Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Bristol-Myers Squibb
Upon determination of eligibility, patients will receive:
Paclitaxel + Estramustine + Carboplatin
Patients will receive weekly paclitaxel and low-dose estramustine, in combination with carboplatin administered either weekly r every four weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adenocarcinoma of the prostate not curable with local treatment
Disease progression while receiving hormonal therapy
Measurable or evaluable disease
Previous treatment with a maximum of one prior chemotherapy regimen
ECOG performance status 0, 1, or 2.
Adequate bone marrow, liver and kidney function
Able to comprehend the nature of this study and give written informed consent
You may not be if
You cannot participate in this study if any of the following apply to you:
Age \< 18 years
History of treatment for an invasive malignancy within five years
